Search research articles
Contact Us
Filters
Showing results (161-170 of 232) with videos related to
Page
of 24
Sort By:
Cancer
|
April 21, 2021
A phase II basket trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART) SWOG S1609: High-grade neuroendocrine neoplasm cohort
Sandip Pravin Patel, Edward Mayerson, Young Kwang Chae, et al.
The Lancet. Oncology
|
July 11, 2014
Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials
Robert K Hills, Sylvie Castaigne, Frederick R Appelbaum, et al.
Haematologica
|
December 16, 2017
Unsatisfactory efficacy in randomized study of reduced-dose CPX-351 for medically less fit adults with newly diagnosed acute myeloid leukemia or other high-grade myeloid neoplasm
Roland B Walter, Megan Othus, Kaysey F Orlowski, et al.
Cancer
|
February 15, 2024
SWOG 1609 cohort 48: anti-CTLA-4 and anti-PD-1 for advanced gallbladder cancer
Sandip P Patel, Elizabeth Guadarrama, Young Kwang Chae, et al.
Scientific Reports
|
March 29, 2020
Association of immunophenotype with expression of topoisomerase II α and β in adult acute myeloid leukemia
Andrew P Michelson, Shannon McDonough, Cheryl L Willman, et al.
Haematologica
|
January 28, 2017
Minimal residual disease prior to allogeneic hematopoietic cell transplantation in acute myeloid leukemia: a meta-analysis
Sarah A Buckley, Brent L Wood, Megan Othus, et al.
Blood
|
January 18, 2013
Significance of FAB subclassification of "acute myeloid leukemia, NOS" in the 2008 WHO classification: analysis of 5848 newly diagnosed patients
Roland B Walter, Megan Othus, Alan K Burnett, et al.
Leukemia & Lymphoma
|
October 13, 2022
Early mortality risk with non-intensive acute myeloid leukemia (AML) therapies: analysis of 1336 patients from MRC/NCRI and SWOG
Megan Othus, Ian Thomas, Xu Wang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 2, 2024
Influence of Nucleophosmin (<i>NPM1</i>) Genotypes on Outcome of Patients With AML: An AIEOP-BFM and COG-SWOG Intergroup Collaboration
Claudia Tregnago, Maddalena Benetton, Rhonda E Ries, et al.
Leukemia
|
August 21, 2024
Optimal prognostic threshold for measurable residual disease positivity by multiparameter flow cytometry in acute myeloid leukemia (AML)
Eduardo Rodríguez-Arbolí, Megan Othus, Sylvie D Freeman, et al.
Page
of 24
Search research articles
Search
Showing results (161-170 of 232) with videos related to
Sort By:
Page
of 24
Cancer
|
April 21, 2021
A phase II basket trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART) SWOG S1609: High-grade neuroendocrine neoplasm cohort
Sandip Pravin Patel, Edward Mayerson, Young Kwang Chae, et al.
The Lancet. Oncology
|
July 11, 2014
Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials
Robert K Hills, Sylvie Castaigne, Frederick R Appelbaum, et al.
Haematologica
|
December 16, 2017
Unsatisfactory efficacy in randomized study of reduced-dose CPX-351 for medically less fit adults with newly diagnosed acute myeloid leukemia or other high-grade myeloid neoplasm
Roland B Walter, Megan Othus, Kaysey F Orlowski, et al.
Cancer
|
February 15, 2024
SWOG 1609 cohort 48: anti-CTLA-4 and anti-PD-1 for advanced gallbladder cancer
Sandip P Patel, Elizabeth Guadarrama, Young Kwang Chae, et al.
Scientific Reports
|
March 29, 2020
Association of immunophenotype with expression of topoisomerase II α and β in adult acute myeloid leukemia
Andrew P Michelson, Shannon McDonough, Cheryl L Willman, et al.
Haematologica
|
January 28, 2017
Minimal residual disease prior to allogeneic hematopoietic cell transplantation in acute myeloid leukemia: a meta-analysis
Sarah A Buckley, Brent L Wood, Megan Othus, et al.
Blood
|
January 18, 2013
Significance of FAB subclassification of "acute myeloid leukemia, NOS" in the 2008 WHO classification: analysis of 5848 newly diagnosed patients
Roland B Walter, Megan Othus, Alan K Burnett, et al.
Leukemia & Lymphoma
|
October 13, 2022
Early mortality risk with non-intensive acute myeloid leukemia (AML) therapies: analysis of 1336 patients from MRC/NCRI and SWOG
Megan Othus, Ian Thomas, Xu Wang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 2, 2024
Influence of Nucleophosmin (<i>NPM1</i>) Genotypes on Outcome of Patients With AML: An AIEOP-BFM and COG-SWOG Intergroup Collaboration
Claudia Tregnago, Maddalena Benetton, Rhonda E Ries, et al.
Leukemia
|
August 21, 2024
Optimal prognostic threshold for measurable residual disease positivity by multiparameter flow cytometry in acute myeloid leukemia (AML)
Eduardo Rodríguez-Arbolí, Megan Othus, Sylvie D Freeman, et al.
Page
of 24